Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 102kWORD 18k
10 October 2018
Question for written answer P-005158-18
to the Commission
Rule 130
Patrizia Toia (S&D)

 Subject:  Costs of moving the European Medicines Agency to Amsterdam
 Answer in writing 

It has been reported in the press that legal proceedings are pending between the EMA (European Medicines Agency) and the company Canary Wharf concerning the payment of EUR 320 million for the rent of the Agency’s headquarters until 2039.

The European Parliament was not sufficiently involved in the decision on the definitive location to which the EMA was to move. An appeal by the Municipality of Milan is still pending before the European Court of Justice, and doubts remain as to whether the new premises to be occupied — albeit only provisionally — by the European Medicines Agency in Amsterdam can be ready by March 2019.

1. Is the Commission considering the desirability of reopening the procedure for deciding where the EMA should be located in future?

2. Does the Commission have any information about the costs already incurred in making the move, and can it supply an estimate of the necessary amount to be borne by the European budget to cover the additional costs associated with the unavailability of premises in 2019 and the possible loss of the court case to Canary Wharf?

Original language of question: IT 
Last updated: 15 October 2018Legal notice